15.67

3.27% -0.53

Corvus Pharmaceuticals Inc (CRVS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$16.20

Aprire:

$16.11

Volume 24 ore:

1.21M

Relative Volume:

0.80

Capitalizzazione di mercato:

$1.32B

Reddito:

Utile/perdita netta:

$-44.17M

Rapporto P/E:

-29.79

EPS:

-0.526

Flusso di cassa netto:

$-35.14M

1 W Prestazione:

+2.89%

1M Prestazione:

+40.41%

6M Prestazione:

+130.78%

1 anno Prestazione:

+268.71%

Intervallo 1D:

$15.27

$16.20

Intervallo di 1 settimana:

$14.93

$16.47

Portata 52W:

$3.96

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Nome

Corvus Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(650) 900-4520

Indirizzo

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRVS Corvus Pharmaceuticals Inc	15.67	1.32B	0	-44.17M	-35.14M	-0.526
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-17	Iniziato	Goldman	Buy
2025-10-13	Iniziato	Barclays	Overweight
2025-01-02	Iniziato	H.C. Wainwright	Buy
2023-08-18	Iniziato	Oppenheimer	Outperform
2021-12-01	Ripresa	Jefferies	Buy
2021-05-27	Iniziato	Cantor Fitzgerald	Overweight
2021-02-10	Downgrade	Mizuho	Buy → Neutral
2019-09-12	Iniziato	Mizuho	Buy
2019-05-29	Iniziato	ROTH Capital	Buy
2017-08-24	Aggiornamento	Credit Suisse	Underperform → Neutral
2017-05-01	Downgrade	Credit Suisse	Neutral → Underperform
2016-04-18	Iniziato	Credit Suisse	Outperform
2016-04-18	Iniziato	Guggenheim	Buy

Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

Jul 11, 2026

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits

Jul 11, 2026

Jul 10, 2026

Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España

Jul 04, 2026

Jul 02, 2026

Corvus Pharmaceuticals (CRVS) Gains 1.42% as Biotech Momentum Lifts Speculative NamesDaily Profile - dars.gov.et

Jul 02, 2026

Jun 27, 2026

Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm

Jun 27, 2026

Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView

Jun 27, 2026

Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17) - TradingView

Jun 27, 2026

Jun 26, 2026

Corvus Pharmaceuticals, Inc. Actuals & Estimates (SWB:C17) - TradingView

Jun 26, 2026

Jun 25, 2026

Corvus Pharmaceuticals, Inc. Actuals & Estimates (DUS:C17) - TradingView

Jun 25, 2026

CRVS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Corvus Pharmaceuticals (CRVS) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView

Jun 25, 2026

Jun 24, 2026

Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView

Jun 24, 2026

Jun 23, 2026

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - Yahoo Finance

Jun 23, 2026

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool

Jun 23, 2026

Jun 17, 2026